Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kestra Medical Technologies (KMTS) Research & Development (2024 - 2026)

Kestra Medical Technologies (KMTS) has disclosed Research & Development for 3 consecutive years, with $5.0 million as the latest value for Q1 2026.

  • Quarterly Research & Development rose 48.29% to $5.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $19.2 million through Jan 2026, up 36.56% year-over-year, with the annual reading at $15.7 million for FY2025, 1.05% up from the prior year.
  • Research & Development for Q1 2026 was $5.0 million at Kestra Medical Technologies, up from $4.9 million in the prior quarter.
  • The five-year high for Research & Development was $5.4 million in Q2 2025, with the low at $3.4 million in Q1 2025.
  • Average Research & Development over 3 years is $4.1 million, with a median of $3.8 million recorded in 2024.
  • The sharpest move saw Research & Development fell 10.23% in 2025, then skyrocketed 48.29% in 2026.
  • Over 3 years, Research & Development stood at $3.5 million in 2024, then soared by 39.01% to $4.9 million in 2025, then grew by 1.93% to $5.0 million in 2026.
  • According to Business Quant data, Research & Development over the past three periods came in at $5.0 million, $4.9 million, and $4.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.